Juneko E. Grilley-Olson
Distinguished in Adult Soft Tissue Sarcoma

Dr. Juneko E. Grilley-Olson

Hematology Oncology | Hematology | Oncology
Duke Health
Duke Cancer Center Sarcoma Clinic
20 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth

Distinguished in Adult Soft Tissue Sarcoma
Duke Health
Duke Cancer Center Sarcoma Clinic
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I am a medical oncologist specializing in bone and soft tissue cancers called sarcomas. Sarcomas occur throughout the body, so I collaborate closely with colleagues from other specialties in a multidisciplinary team. I view my role in caring for someone's cancer as as privilege and strive to work together with each patient to ensure the best treatment decisions are made, all the while embracing each person's uniqueness as an individual. I see adult patients of all ages, but have a particular interest in the unique challenges facing a young adults with cancer. When I'm not working, you can find me exploring the outdoors with my family, traveling, and cooking.

Dr. Grilley-Olson is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Fibrosarcoma.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles and participated in 2 clinical trials in the study of Adult Soft Tissue Sarcoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Med, Medical Oncology
Fellowships
Hematology and Medical Oncology, University of North Carolina at Chapel Hill
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Duke Cancer Center Sarcoma Clinic
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-613-5550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cetuximab, PD 0332991
Study Phase: Phase 1/Phase 2
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, 5-Fluorouracil, Hydroxyurea, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

63 Total Publications

ASO Visual Abstract: Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors-a Feasibility Study.
ASO Visual Abstract: Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors-a Feasibility Study.
Journal: Annals of surgical oncology
Published: August 18, 2025
View All 63 Publications
Similar Doctors
Richard F. Riedel
Elite in Adult Soft Tissue Sarcoma
Dr. Richard F. Riedel
Oncology
Elite in Adult Soft Tissue Sarcoma
Dr. Richard F. Riedel
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I am a medical oncologist who focuses on bone and soft tissue cancers called sarcomas. I love spending time with my patients. They often have a sense of awareness about their condition that’s truly unique and rewarding. I partner with each patient so they know the full set of options available for treatment and can make an informed decision about the approach that is best for them. I’ve wanted to pursue medicine for as long as I can remember. I find cancer fascinating because of its ability to evade the immune system. The body fails to recognize cancer as being foreign. When I am not at work, I love spending time with my family and enjoy long distance running. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma.

Daniel J. George
Distinguished in Adult Soft Tissue Sarcoma
Dr. Daniel J. George
Urology | Hematology | Oncology
Distinguished in Adult Soft Tissue Sarcoma
Dr. Daniel J. George
Urology | Hematology | Oncology

Duke Cancer Center Genitourinary (GU) Clinic

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-668-6688
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Michael R. Harrison
Distinguished in Adult Soft Tissue Sarcoma
Dr. Michael R. Harrison
Oncology | Hematology
Distinguished in Adult Soft Tissue Sarcoma
Dr. Michael R. Harrison
Oncology | Hematology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I specialize in treating people with genitourinary (GU) cancers, such as bladder, prostate, testicular and kidney cancer. I don’t treat other types of cancer across the breadth of tumors like some oncologists in the community may, such as blood cancer, breast cancer or lung cancer. My focus has allowed me to gain deep expertise in GU cancers and to stay abreast of the newest treatment advances, clinical research and so on for those specific GU cancers. As a medical oncologist, I meet patients at one of the scariest moments of their lives. I try to help educate them to make a decision about their disease and its process, and what their treatment options may be, so we can come to a shared decision about what might be the best option. The teaching aspect really strikes home for me. Both of my parents are teachers. The root word for “doctor” in Latin means “to teach.” So that is something I’m both naturally called to do and enjoy doing. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Clear Cell Sarcoma, and Prostatectomy.

VIEW MORE ADULT SOFT TISSUE SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grilley-Olson's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiosarcoma of the Scalp
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Angiosarcoma of the Scalp.
      See more Angiosarcoma of the Scalp experts
    • Bone Tumor
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Epithelioid Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Epithelioid Sarcoma.
      See more Epithelioid Sarcoma experts
    • Fibrosarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Fibrosarcoma.
      See more Fibrosarcoma experts
    View All 12 Distinguished Conditions
    • Advanced
    • Angiosarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Angiosarcoma of the Liver
      Dr. Grilley-Olson is
      Advanced
      . Learn about Angiosarcoma of the Liver.
      See more Angiosarcoma of the Liver experts
    • Chondrosarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Chondrosarcoma.
      See more Chondrosarcoma experts
    • Epithelial-Myoepithelial Carcinoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Epithelial-Myoepithelial Carcinoma.
      See more Epithelial-Myoepithelial Carcinoma experts
    • Ewing Sarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Ewing Sarcoma.
      See more Ewing Sarcoma experts
    • Ganglioneuroblastoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Ganglioneuroblastoma.
      See more Ganglioneuroblastoma experts
    View All 13 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Grilley-Olson is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adrenal Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Agranulocytosis
      Dr. Grilley-Olson is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.